BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Georgiopoulos G, Alexopoulou A, Pouriki S, Vasilieva L, Laina A, Bampatsias D, Mani I, Kontogiannis C, Tousoulis D, Stamatelopoulos K, Dourakis SP. Pegylated interferon and ribavirin treatment for chronic hepatitis C deteriorates subclinical markers of vascular function. Hellenic J Cardiol 2019;60:143-5. [PMID: 31146885 DOI: 10.1016/j.hjc.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Shan W, Hong D, Zhu J, Zhao Q. Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy. Comput Math Methods Med 2020;2020:1391583. [PMID: 33029193 DOI: 10.1155/2020/1391583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]